Additionally, in a mouse lymphoma model, which was resistant to ibrutinib monotherapy, the combination of ibrutinib with anti-PD-L1 therapy significantly improved survival compared to anti-PD-L1 therapy alone [206]. The gene discussed is CD274; the disease is lymphoma.